A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061

Cancer

Volumn 120, Issue 8, 2014, Pages 1194-1202

  Rudek, Michelle A ^a   Moore, Page C ^b   Mitsuyasu, Ronald T ^c   Dezube, Bruce J ^d   Aboulafia, David ^e   Gerecitano, John ^f   Sullivan, Ryan ^g   Cianfrocca, Mary E ^h   Henry, David H ⁱ   Ratner, Lee ^j   Haigentz, Missak ^k   Dowlati, Afshin ^l   Little, Richard F ^m   Ivy, Susan Percy ^l   Deeken, John F ⁿ  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ PENNSYLVANIA HOSPITAL   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l CASE WESTERN RESERVE UNIVERSITY   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ Inova Comprehensive Cancer and Research Center   (United States)

more..

Author keywords

clinical trial; highly active antiretroviral therapy (HAART); human immunodeficiency virus (HIV); phase 1; sunitinib

Indexed keywords

EFAVIRENZ; N DEETHYLSUNITINIB; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; SUNITINIB;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOPIGMENTATION; LIMB PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEOPLASM; NEUTROPENIA; NON ACQUIRED IMMUNODEFICIENCY SYNDROME DEFINING CANCER; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STEADY STATE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VIRUS LOAD; WOUND COMPLICATION; WOUND DEHISCENCE;

CLINICAL TRIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART); HUMAN IMMUNODEFICIENCY VIRUS (HIV); PHASE 1; SUNITINIB;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; PYRROLES; RITONAVIR;

EID: 84898045270     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28554     Document Type: Article

References (33)

1. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007; 21: 685-692.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338: 853-860.
3. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD,. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006; 24: 1383-1388.
4. Shiels MS, Pfeiffer RM, Hall HI, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA. 2011; 305: 1450-1459.
5. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005; 97: 425-432.
6. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011; 103: 753-762.
7. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003; 21: 3447-3453.
8. Deeken JF, Tjen-A-Looi AL, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012; 55: 1228-1235.
9. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007; 45: 103-110.
10. Hammer SM, Saag MS, Schechter M, et al. International AIDS Society-USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006; 296: 827-843.
11. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2011. http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed on June 1, 2013.
12. Rudek MA, Flexner C, Ambinder RF,. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011; 12: 905-912.
13. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW,. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003; 36: 1585-1592.
14. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003; 2: 1011-1021.
15. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM,. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2: 471-478.
16. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327-337.
17. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 101: 3597-3605.
18. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003; 63: 4009-4016.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
20. Scher HI, Halabi S, tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.
21. Krown SE, Metroka C, Wernz JC,. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989; 7: 1201-1207.
22. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.
23. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
24. Cheson BD, Bennett JM, Kopecky KJ, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21: 4642-4649.
25. Rais R, Zhao M, He P, Xu L, Deeken JF, Rudek MA,. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Biomed Chromatogr. 2012; 26: 1315-1324.
26. Houk BE, Bello CL, Kang D, Amantea M,. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009; 15: 2497-2506.
27. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ,. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010; 66: 357-371.
28. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355: 2283-2296.
29. Pfizer,. SUTENT (sunitinib malate) Capsules, Oral Prescribing Information. New York, NY: Pfizer; 2011.
30. Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH,. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther. 2012; 341: 164-173.
31. Tang SC, Lagas JS, Lankheet NA, et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer. 2012; 130: 223-233.
32. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998; 37: 3594-3601.
33. Bunting KD, Zhou S, Lu T, Sorrentino BP,. Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. Blood. 2000; 96: 902-909.